These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 16831964)

  • 1. Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease).
    Weinstock-Guttman B; Ramanathan M; Lincoff N; Napoli SQ; Sharma J; Feichter J; Bakshi R
    Arch Neurol; 2006 Jul; 63(7):957-63. PubMed ID: 16831964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brain abnormalities in neuromyelitis optica.
    Pittock SJ; Lennon VA; Krecke K; Wingerchuk DM; Lucchinetti CF; Weinshenker BG
    Arch Neurol; 2006 Mar; 63(3):390-6. PubMed ID: 16533966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuromyelitis optica treatment: analysis of 36 patients.
    Bichuetti DB; Lobato de Oliveira EM; Oliveira DM; Amorin de Souza N; Gabbai AA
    Arch Neurol; 2010 Sep; 67(9):1131-6. PubMed ID: 20837859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica.
    Kim SH; Kim W; Park MS; Sohn EH; Li XF; Kim HJ
    Arch Neurol; 2011 Apr; 68(4):473-9. PubMed ID: 21149806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Mitoxantrone for the treatment of Japanese patients with multiple sclerosis].
    Komori M; Tanaka M; Muramoto E; Ohno M; Matsumoto R; Murase N; Kitagawa N; Saida T
    Rinsho Shinkeigaku; 2007 Jul; 47(7):401-6. PubMed ID: 17710882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis.
    Vollmer T; Panitch H; Bar-Or A; Dunn J; Freedman MS; Gazda SK; Campagnolo D; Deutsch F; Arnold DL
    Mult Scler; 2008 Jun; 14(5):663-70. PubMed ID: 18424479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of mitoxantrone, as an initial therapy, in multiple sclerosis: experience in an Indian tertiary care setting.
    Singhal BS; Geeta S; Hundalani SG; Menon S
    Neurol India; 2009; 57(4):418-23. PubMed ID: 19770542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety.
    Zipoli V; Portaccio E; Hakiki B; Siracusa G; Sorbi S; Amato MP
    J Neurol Sci; 2008 Mar; 266(1-2):25-30. PubMed ID: 17870094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years.
    Kim SH; Kim W; Li XF; Jung IJ; Kim HJ
    Arch Neurol; 2011 Nov; 68(11):1412-20. PubMed ID: 21747007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients.
    Jacob A; Weinshenker BG; Violich I; McLinskey N; Krupp L; Fox RJ; Wingerchuk DM; Boggild M; Constantinescu CS; Miller A; De Angelis T; Matiello M; Cree BA
    Arch Neurol; 2008 Nov; 65(11):1443-8. PubMed ID: 18779415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spectrum of pediatric neuromyelitis optica.
    Lotze TE; Northrop JL; Hutton GJ; Ross B; Schiffman JS; Hunter JV
    Pediatrics; 2008 Nov; 122(5):e1039-47. PubMed ID: 18838462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical characteristics, course and prognosis of relapsing Devic's Neuromyelitis Optica.
    Ghezzi A; Bergamaschi R; Martinelli V; Trojano M; Tola MR; Merelli E; Mancardi L; Gallo P; Filippi M; Zaffaroni M; Comi G;
    J Neurol; 2004 Jan; 251(1):47-52. PubMed ID: 14999489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial.
    Krapf H; Morrissey SP; Zenker O; Zwingers T; Gonsette R; Hartung HP;
    Neurology; 2005 Sep; 65(5):690-5. PubMed ID: 16157900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon-beta(1b) treatment in neuromyelitis optica.
    Tanaka M; Tanaka K; Komori M
    Eur Neurol; 2009; 62(3):167-70. PubMed ID: 19590215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expanding the spectrum of neuromyelitis optica: friend or foe?
    Behbehani R
    Curr Opin Ophthalmol; 2007 Nov; 18(6):459-62. PubMed ID: 18162996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuromyelitis optica immunoglobulins as a marker of disease activity and response to therapy in patients with neuromyelitis optica.
    Weinstock-Guttman B; Miller C; Yeh E; Stosic M; Umhauer M; Batra N; Munschauer F; Zivadinov R; Ramanathan M
    Mult Scler; 2008 Sep; 14(8):1061-7. PubMed ID: 18573816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of mitoxantrone in neuromyelitis optica spectrum: clinical and neuroradiological study.
    Cabre P; Olindo S; Marignier R; Jeannin S; Merle H; Smadja D;
    J Neurol Neurosurg Psychiatry; 2013 May; 84(5):511-6. PubMed ID: 23138769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma exchange for acute attacks of CNS demyelination: Predictors of improvement at 6 months.
    Llufriu S; Castillo J; Blanco Y; Ramió-Torrentà L; Río J; Vallès M; Lozano M; Castellà MD; Calabia J; Horga A; Graus F; Montalban X; Saiz A
    Neurology; 2009 Sep; 73(12):949-53. PubMed ID: 19770470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuromyelitis optica in France: a multicenter study of 125 patients.
    Collongues N; Marignier R; Zéphir H; Papeix C; Blanc F; Ritleng C; Tchikviladzé M; Outteryck O; Vukusic S; Fleury M; Fontaine B; Brassat D; Clanet M; Milh M; Pelletier J; Audoin B; Ruet A; Lebrun-Frenay C; Thouvenot E; Camu W; Debouverie M; Créange A; Moreau T; Labauge P; Castelnovo G; Edan G; Le Page E; Defer G; Barroso B; Heinzlef O; Gout O; Rodriguez D; Wiertlewski S; Laplaud D; Borgel F; Tourniaire P; Grimaud J; Brochet B; Vermersch P; Confavreux C; de Seze J
    Neurology; 2010 Mar; 74(9):736-42. PubMed ID: 20194912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis.
    Gladstone DE; Zamkoff KW; Krupp L; Peyster R; Sibony P; Christodoulou C; Locher E; Coyle PK
    Arch Neurol; 2006 Oct; 63(10):1388-93. PubMed ID: 16908728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.